Breakthrough in Early Diagnosis and Treatment of Type 1 Diabetes

Strategic Insights -

A collaborative study between scientists from the University Campus Bio-Medico in Rome, Italy, and Generex's subsidiary, Antigen Express, Inc., has published results in the April issue of Hormone and Metabolism Research. The study, entitled "Recognition of Ii-Key/MHC Class II Epitope Hybrids Derived from Proinsulin and GAD Peptides by T Cells in Type 1 Diabetes," presents a novel approach to identifying and possibly treating Type 1 diabetes. The researchers employed the Ii-Key technology, developed at Antigen Express, to enhance the potency of antigenic peptides while maintaining their specificity.

Key Takeaways:

  • The study utilized the Ii-Key technology to develop peptide hybrids from proinsulin and GAD65 proteins, which showed high sensitivity in detecting autoimmune T cells in patients with Type 1 diabetes.
  • The Ii-Key modified peptides demonstrated improved ability to identify autoimmune T cells compared to unmodified peptides.
  • The study highlights the potential of the Ii-Key hybrid technique in designing clinically strategic plans to suppress autoimmunity associated with Type 1 diabetes.
  • Generex has developed a proprietary platform technology for delivering drugs into the human body through the oral cavity, revolutionizing drug delivery systems.
  • The HER2 peptide, an Ii-Key modified peptide, is currently in a Phase II clinical trial as an immunotherapeutic vaccine for patients with breast cancer.
  • Professor Paolo Pozzilli from the University Campus Bio-Medico emphasized the significance of early diagnosis and management of Type 1 diabetes, stating that the current study has clear potential in this regard.

Statistics:

  • Type 1 diabetes is an autoimmune disease directed at insulin-producing cells in the pancreas.
  • The study reports that Ii-Key modified peptides from proinsulin and GAD65 proteins were capable of detecting autoimmune T cells in the blood from Type 1 diabetes patients (95% sensitivity).
  • Unmodified peptides showed lower sensitivity in detecting autoimmune T cells compared to Ii-Key modified peptides.
  • The Ii-Key technology has been successfully used to increase the potency of various antigenic peptides.

Sources:

  • Hormone and Metabolism Research, April issue
  • Generex Biotechnology Corp. press release
  • University Campus Bio-Medico, Rome, Italy
  • Antigen Express, Inc.
  • Generex.com
  • AntigenExpress.com